$8.62
1.77% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US29772L1089
Symbol
ETON
Sector
Industry

Eton Pharmaceuticals, Inc. Target price 2024 - Analyst rating & recommendation

Eton Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
100%

Eton Pharmaceuticals, Inc. Price Target

Target Price $13.00
Price $8.62
Potential
Number of Estimates 2
2 Analysts have issued a price target Eton Pharmaceuticals, Inc. 2025 . The average Eton Pharmaceuticals, Inc. target price is $13.00. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 2 analysts: 2 Analysts recommend Eton Pharmaceuticals, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Eton Pharmaceuticals, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Eton Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 31.64 37.11
48.89% 17.27%
EBITDA Margin -0.92% -6.20%
97.00% 576.44%
Net Margin -3.26% -12.49%
92.54% 283.67%

2 Analysts have issued a sales forecast Eton Pharmaceuticals, Inc. 2024 . The average Eton Pharmaceuticals, Inc. sales estimate is

$37.1m
Unlock
. This is
18.25% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$37.7m 20.18%
Unlock
, the lowest is
$36.5m 16.32%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $31.6m 48.89%
2024
$37.1m 17.27%
Unlock
2025
$67.8m 82.71%
Unlock
2026
$91.7m 35.30%
Unlock
2027
$115m 25.27%
Unlock
2028
$139m 21.03%
Unlock

1 Analyst has issued an EBITDA forecast Eton Pharmaceuticals, Inc. 2024 . The average Eton Pharmaceuticals, Inc. EBITDA estimate is

$-2.3m
Unlock
. This is
56.36% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-2.3m 56.36%
Unlock
, the lowest is
$-2.3m 56.36%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-290k 95.54%
2024
$-2.3m 693.10%
Unlock
2025
$17.0m 839.13%
Unlock

EBITDA Margin

2023 -0.92% 97.00%
2024
-6.20% 576.44%
Unlock
2025
25.08% 504.52%
Unlock

1 Analyst has issued a net profit forecast Eton Pharmaceuticals, Inc. 2024 . The average Eton Pharmaceuticals, Inc. net profit estimate is

$-4.6m
Unlock
. This is
30.69% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-4.6m 30.69%
Unlock
, the lowest is
$-4.6m 30.69%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-1.0m 88.89%
2024
$-4.6m 350.49%
Unlock
2025
$12.4m 366.38%
Unlock

Net Margin

2023 -3.26% 92.54%
2024
-12.49% 283.67%
Unlock
2025
18.23% 245.96%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.04 -0.18
88.89% 350.00%
P/E negative
EV/Sales 5.66

1 Analysts have issued a Eton Pharmaceuticals, Inc. forecast for earnings per share. The average Eton Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.18
Unlock
. This is
30.77% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.18 30.77%
Unlock
, the lowest is
$-0.18 30.77%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.04 88.89%
2024
$-0.18 350.00%
Unlock
2025
$0.48 366.67%
Unlock

P/E ratio

Current -33.20 88.64%
2024
-47.89 44.25%
Unlock
2025
17.96 137.50%
Unlock

Based on analysts' sales estimates for 2024, the Eton Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 6.69 140.65%
2024
5.66 15.44%
Unlock
2025
3.10 45.27%
Unlock
2026
2.29 26.09%
Unlock
2027
1.83 20.17%
Unlock
2028
1.51 17.38%
Unlock

P/S ratio

Current 7.10 114.68%
2024
6.00 15.43%
Unlock
2025
3.29 45.27%
Unlock
2026
2.43 26.09%
Unlock
2027
1.94 20.17%
Unlock
2028
1.60 17.38%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today